125 related articles for article (PubMed ID: 20218013)
1. Pharmacokinetics of methotrexate in solid tumors.
Jain RK; Wei J; Gullino PM
J Pharmacokinet Biopharm; 1979 Apr; 7(2):181-94. PubMed ID: 20218013
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats.
Stehle G; Wunder A; Sinn H; Schrenk HH; Schütt S; Frei E; Hartung G; Maier-Borst W; Heene DL
Anticancer Drugs; 1997 Oct; 8(9):835-44. PubMed ID: 9402310
[TBL] [Abstract][Full Text] [Related]
3. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats.
Devineni D; Klein-Szanto A; Gallo JM
Cancer Chemother Pharmacol; 1996; 38(6):499-507. PubMed ID: 8823490
[TBL] [Abstract][Full Text] [Related]
4. [PEGylated polyamidoamine dendrimer/methotrexate complex: pharmacokinetics and anti-tumor activity in normal and tumor-bearing rodents].
Kong SY; Tang GT; Pei YY; Jiang YY
Yao Xue Xue Bao; 2009 Jan; 44(1):85-90. PubMed ID: 19350828
[TBL] [Abstract][Full Text] [Related]
5. Slow release properties and liver-targeting characteristics of methotrexate erythrocyte carriers.
Yuan SH; Ge WH; Huo J; Wang XH
Fundam Clin Pharmacol; 2009 Apr; 23(2):189-96. PubMed ID: 19298236
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by 19F-magnetic resonance spectroscopy.
Katzir I; Shani J; Wolf W; Chatterjee-Parti S; Berman E
Cancer Invest; 2000; 18(1):20-7. PubMed ID: 10701363
[TBL] [Abstract][Full Text] [Related]
7. CAN a P-gp modulator assist in the control of methotrexate concentrations in the rat brain? -inhibitory effects of rhodamine 123, a specific substrate for P-gp, on methotrexate excretion from the rat brain and its optimal route of administration.
Ogushi N; Sasaki K; Shimoda M
J Vet Med Sci; 2017 Feb; 79(2):320-327. PubMed ID: 27916761
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of methotrexate in the extracellular fluid of brain C6-glioma after intravenous infusion in rats.
Dukic S; Heurtaux T; Kaltenbach ML; Hoizey G; Lallemand A; Gourdier B; Vistelle R
Pharm Res; 1999 Aug; 16(8):1219-25. PubMed ID: 10468023
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy.
Dupuis C; Mercier C; Yang C; Monjanel-Mouterde S; Ciccolini J; Fanciullino R; Pourroy B; Deville JL; Duffaud F; Bagarry-Liegey D; Durand A; Iliadis A; Favre R
Anticancer Drugs; 2008 Mar; 19(3):267-73. PubMed ID: 18510172
[TBL] [Abstract][Full Text] [Related]
11. Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments.
Balthasar JP; Fung HL
J Pharm Sci; 1996 Oct; 85(10):1035-43. PubMed ID: 8897267
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma.
Wunder A; Stehle G; Schrenk HH; Hartung G; Heene DL; Maier-Borst W; Sinn H
Int J Cancer; 1998 Jun; 76(6):884-90. PubMed ID: 9626357
[TBL] [Abstract][Full Text] [Related]
13. Interstitial methotrexate kinetics in primary breast cancer lesions.
Müller M; Brunner M; Schmid R; Mader RM; Bockenheimer J; Steger GG; Steiner B; Eichler HG; Blöchl-Daum B
Cancer Res; 1998 Jul; 58(14):2982-5. PubMed ID: 9679959
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats.
Park JM; Ahn BN; Yoon EJ; Lee MG; Shim CK; Kim CK
Biopharm Drug Dispos; 1994 Jul; 15(5):391-407. PubMed ID: 7981428
[TBL] [Abstract][Full Text] [Related]
15. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats.
Park JM; Moon CH; Lee MG
Res Commun Mol Pathol Pharmacol; 1996 Sep; 93(3):353-62. PubMed ID: 8896046
[TBL] [Abstract][Full Text] [Related]
17. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
18. Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier.
Han JH; Oh YK; Kim DS; Kim CK
Int J Pharm; 1999 Oct; 188(1):39-47. PubMed ID: 10528081
[TBL] [Abstract][Full Text] [Related]
19. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats.
Stehle G; Sinn H; Wunder A; Schrenk HH; Schütt S; Maier-Borst W; Heene DL
Anticancer Drugs; 1997 Aug; 8(7):677-85. PubMed ID: 9311444
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
